Breast Cancers Boost Growth by Remotely Disrupting Immunity in Animal Models
Complete the form below to unlock access to ALL audio articles.
Researchers at Baylor College of Medicine and collaborating institutions have identified a strategy cancerous tumors use to remotely disrupt the development of an immune response that could stop their growth.
Published in the journal Cell Stem Cell, the study shows in animal models that breast cancer tumors send molecular signals to the bone marrow, the birthplace of immune cells. The signals alter the natural environment of the bone marrow in such a way that it suppresses the response to fight back the tumor. Interestingly, these changes persist long after tumor removal.
The researchers also identified ways to accelerate the restoration of the normal conditions in the bone marrow after tumor removal, speeding up the recovery of the immune system. The findings warrant further research that could potentially lead to improved treatments for patients.
Want more breaking news?
Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.Subscribe for FREE
The team found that even small tumors can affect the body profoundly as they trigger multiple changes in the bone marrow.
“Breast cancer tumors promote the over production of bone marrow cells called osteoprogenitor cells, which will later contribute to the formation of new bone,” said first author Dr. Xiaoxin Hao, postdoctoral associate in the Zhang lab.
In addition, other cells, the progenitors of cells that give rise to immune cells, also grow in numbers. Importantly, these progenitors also change their typical location within the bone marrow, relocating near the osteoprogenitor cells and establishing a new cell-to-cell communication with these cells, particularly with a subset called granulocyte-monocyte progenitors (GMPs).
“We think that this osteoprogenitor-GMP communication is key, because GMPs give rise to neutrophils and monocytes, immune cells that have long been known to accumulate in some breast cancer tumors in patients and breast cancer mouse models and help promote tumor growth by suppressing the anti-tumor immune response,” Hao said.
The researchers were surprised to find that after they removed the tumor, which they considered the source of the problem, the disruption of the bone marrow did not recover immediately.
“We observed this in animal models,” Hao said. “In some patients, we have seen that even more than 40 weeks after removing the tumor, increased numbers of neutrophils remain in their blood, which is clinically relevant.”
In some cases, tumor removal is followed by immunotherapy, which relies on an intact immune system for its success. “Our findings suggest that at least in some patients the immune system is still compromised after removing the tumor, likely reducing the beneficial effects of immunotherapy,” said Zhang, a member of the Dan L Duncan Comprehensive Cancer Center and a McNair Scholar.
In addition, the findings have implications for metastasis. Metastasis may arise years or even decades after the tumor has been surgically removed seeded by residual cancer cells left behind after the surgery. “An immunosuppressive effect lingering after the surgery may create an environment favorable for the residual cancer cells to proliferate and metastasize,” Hao said.
The researchers also identified protein MMP-13 as an essential mediator of the crosstalk between osteoprogenitor cells and GMPs. “We showed that if we eliminate or inhibit MMP-13, we can accelerate the recovery of the immune system and restore the efficacy of immunotherapies,” Hao said.
“Our findings suggest a new modality of treatment that is very different from the current strategies. It’s not targeting the cancer cells, it’s not targeting immune T cells that attack cancer cells, it’s targeting the whole organism. It’s trying to remove a kind of shadow cast over the entire immune system,” Zhang said. “This is just the beginning of a series of studies on how tumors alter the whole body. Our findings support continuing our research on this path, and we hope it will lead to the identification of improved treatments for cancer patients.”
Reference: Hao X, Shen Y, Chen N, et al. Osteoprogenitor-GMP crosstalk underpins solid tumor-induced systemic immunosuppression and persists after tumor removal. Cell Stem Cell. 2023;30(5):648-664.e8. doi: 10.1016/j.stem.2023.04.005
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.